The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

    Shunjun Jiang
    Shunjun Jiang
    Hengrui Liang
    Hengrui Liang
    Zhichao Liu
    Zhichao Liu
    Shen Zhao
    Shen Zhao
    Yalei Zhang
    Yalei Zhang

    The oncologist, 2020.

    Cited by: 0|Bibtex|Views0|Links
    WOS

    Abstract:

    Anlotinib can benefit patients with advanced NSCLC with BM and is highly potent in the management of intracranial lesions. Its special effect on BM and cerebral tissue merits further investigation. (ClinicalTrials.gov ID: NCT02388919).

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments